Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Pneumo News
Erschienen in:

27.06.2024 | COPD-Exazerbation | CME Fortbildung

Risiken, Therapieoptionen, Prävention

Exazerbationen bei COPD: sicher beurteilen, adäquat behandeln

verfasst von: Dr. med. Sarah-Christin Mavi, PD Dr. med. Franziska Trudzinski, Dr. med. Konstantina Kontogianni, Prof. Dr. med. Frederik Trinkmann

Erschienen in: Pneumo News | Ausgabe 3/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Die Exazerbation einer chronisch obstruktiven Lungenerkrankung geht mit erheblichen Risiken für den Patienten einher. Welches praktische Vorgehen ist angezeigt, um den Schaden zu begrenzen und Folgeereignisse zu vermeiden? Und was kann man zur Prävention empfehlen? …
Literatur
1.
Halpin DMG et al. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. Int J Tuberc Lung Dis. 2019;23(11):1131-41
2.
3.
Soler-Cataluna JJ et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-31
4.
Celli BR et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med. 2021;204(11):1251-8
5.
Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398S-401S
6.
Calverley PMA et al. International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. Am J Respir Crit Care Med. 2022;206(1):25-33
7.
Reilev M et al. Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD. Respirology. 2019;24(12):1183-90
8.
Austin MA et al. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010;341:c5462
9.
Oczkowski S et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. Eur Respir J. 2022;59(4):2101574
10.
Westhoff M et al. [Ten key messages of the S2k guideline on noninvasive mechanical ventilation in acute respiratory failure]. Med Klin Intensivmed Notfmed. 2023;118(8):656-9
11.
van Geffen WH et al. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev. 2016;2016(8):CD011826
12.
Barr RG et al. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ. 2003;327(7416):643
13.
Waljee AK et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415
14.
Sivapalan P et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. BMJ Open Respir Res. 2019;6(1):e000407
15.
Leuppi JD et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-31
16.
Bafadhel M et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662-71
17.
Vollenweider DJ et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;10(10):CD010257
18.
Nouira S et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet. 2001;358(9298):2020-5
19.
Chen K et al. Procalcitonin for Antibiotic Prescription in Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review, Meta-Analysis, and Clinical Perspective. Pulm Ther. 2020;6(2):201-14
20.
Stockley RA et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638-45
21.
Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786-96
22.
23.
Lindenauer PK et al. Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. JAMA. 2020;323(18):1813-23
24.
Roche N et al. COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study. Eur Respir J. 2017;50(suppl 61):OA1487
25.
Mannino DM et al. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100(1):115-22
26.
Curkendall SM et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63-70
27.
Trinkmann F et al. Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)-Current Considerations for Clinical Practice. J Clin Med. 2019;8(1):69
28.
Feary JR et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956-62
29.
Vogelmeier CF et al. Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany. BMJ Open Respir Res. 2024;11(1):e002153
30.
Lipson DA et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020;201(12):1508-16
31.
Martinez FJ et al. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med. 2021;203(5):553-64
32.
Strange C et al. Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study. Int J Chron Obstruct Pulmon Dis. 2023;18:2245-56
33.
Vogelmeier CF et al. COPD Exacerbation History and Impact on Future Exacerbations - 8-Year Retrospective Observational Database Cohort Study from Germany. Int J Chron Obstruct Pulmon Dis. 2021;16:2407-17
34.
Hewitt R et al. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158-74
35.
Robert Koch-Institut, Epid Bull. 2020;34:1-68
36.
Modin D et al. Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis. Eur J Heart Fail. 2023;25(9):1685-92
37.
Walters JA et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1(1):CD001390
38.
Falsey AR et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749-59
39.
Walsh EE et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023;388(16):1465-77
40.
Papi A et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023;388(7):595-608
41.
Wilson E et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023;389(24):2233-44
42.
Metadaten
Titel
Risiken, Therapieoptionen, Prävention
Exazerbationen bei COPD: sicher beurteilen, adäquat behandeln
verfasst von
Dr. med. Sarah-Christin Mavi
PD Dr. med. Franziska Trudzinski
Dr. med. Konstantina Kontogianni
Prof. Dr. med. Frederik Trinkmann
Publikationsdatum
27.06.2024

Weitere Artikel der Ausgabe 3/2024

Umweltnoxen begünstigen Asthma und Allergien

Kognition und Gedächtnis nach COVID-19-Infektion

Exazerbationen bei Bronchiektasen: Welche Strategien helfen?

Beinbewegungen im Schlaf als Indikator für kardiovaskuläres Risiko

Finale Daten zum Gesamtüberleben für Crizotinib bei ROS-1-Rearrangement

Ozon: Belastungsfaktor für Pollenallergiker